Literature DB >> 21849624

Drug discontinuation effects are part of the pharmacology of a drug.

Marcus M Reidenberg1.   

Abstract

Most reviews of drug withdrawal effects focus on drugs of potential abuse such as opioids, benzodiazepines, etc. Abrupt discontinuation of many other drugs used in medicine cause withdrawal syndromes, some of which can be fatal. Discontinuation of a number of cardiovascular drugs can increase risk of cardiovascular events above that of people not taking these drugs. These include β-adrenergic receptor antagonists, aspirin, HMG-CoA reductase inhibitors (statins), and heparin. Rebound hypertension occurs after abrupt cessation of many antihypertensive drugs. The possibility of discontinuation syndromes has usually been neglected until adverse clinical events force them to be noticed. Attention to the possibility of drug discontinuation effects is an important part of drug safety evaluation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849624      PMCID: PMC3200000          DOI: 10.1124/jpet.111.183285

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

1.  Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.

Authors:  U Laufs; S Wassmann; S Hilgers; N Ribaudo; M Böhm; G Nickenig
Journal:  Am J Cardiol       Date:  2001-12-01       Impact factor: 2.778

Review 2.  Epidemiologic review of the calcium channel blocker drugs. An up-to-date perspective on the proposed hazards.

Authors:  J R Kizer; S E Kimmel
Journal:  Arch Intern Med       Date:  2001-05-14

3.  Withdrawal of statins in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Christian W Hamm; Ulrich Laufs; Michael Böhm; Steven Snapinn; Harvey D White
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

4.  Health care reform and the need for comparative-effectiveness research.

Authors:  Alvin I Mushlin; Hassan Ghomrawi
Journal:  N Engl J Med       Date:  2010-01-06       Impact factor: 91.245

5.  Withdrawal of statins increases event rates in patients with acute coronary syndromes.

Authors:  Christopher Heeschen; Christian W Hamm; Ulrich Laufs; Steven Snapinn; Michael Böhm; Harvey D White
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

6.  Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.

Authors:  Nick R Bijsterveld; Arno H Moons; Joost C M Meijers; Jan G P Tijssen; Harry R Büller; Marcel Levi; Ron J G Peters
Journal:  J Am Coll Cardiol       Date:  2002-03-06       Impact factor: 24.094

Review 7.  Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.

Authors:  K Black; C Shea; S Dursun; S Kutcher
Journal:  J Psychiatry Neurosci       Date:  2000-05       Impact factor: 6.186

8.  Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies.

Authors:  Nick R Bijsterveld; Ron J G Peters; Sabina A Murphy; Peter J L M Bernink; Jan G P Tijssen; Marc Cohen
Journal:  J Am Coll Cardiol       Date:  2003-12-17       Impact factor: 24.094

9.  Antiplatelet drug discontinuation is a risk factor for ischemic stroke.

Authors:  Igor Sibon; Jean-Marc Orgogozo
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

Review 10.  Endocrine withdrawal syndromes.

Authors:  Ze'ev Hochberg; Karel Pacak; George P Chrousos
Journal:  Endocr Rev       Date:  2003-08       Impact factor: 19.871

View more
  17 in total

Review 1.  Coming safely to a stop: a review of platelet activity after cessation of antiplatelet drugs.

Authors:  Isobel Ford
Journal:  Ther Adv Drug Saf       Date:  2015-08

Review 2.  Antidepressant Withdrawal and Rebound Phenomena.

Authors:  Jonathan Henssler; Andreas Heinz; Lasse Brandt; Tom Bschor
Journal:  Dtsch Arztebl Int       Date:  2019-05-17       Impact factor: 5.594

3.  In Reply.

Authors:  Jonathan Henssler; Lasse Brandt; Andreas Heinz; Tom Bschor
Journal:  Dtsch Arztebl Int       Date:  2019-10-04       Impact factor: 5.594

Review 4.  Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines: the rationale for serum BZD concentration monitoring.

Authors:  Anna Basińska-Szafrańska
Journal:  Eur J Clin Pharmacol       Date:  2021-01-03       Impact factor: 2.953

5.  Deprescribing trials: A focus on adverse drug withdrawal events.

Authors:  Joseph T Hanlon; Shelly L Gray
Journal:  J Am Geriatr Soc       Date:  2022-05-21       Impact factor: 7.538

Review 6.  Approaches to Gradual Dose Reduction of Chronic Off-Label Antipsychotics Used for Behavioral and Psychological Symptoms of Dementia.

Authors:  Jennifer Tjia; Marcus M Reidenberg; Jacob N Hunnicutt; Kelli Paice; Jennifer L Donovan; Abir Kanaan; Becky A Briesacher; Kate L Lapane
Journal:  Consult Pharm       Date:  2015-10

7.  Avoiding Adverse Drug Withdrawal Events When Stopping Unnecessary Medications According to the STOPPFrail Criteria.

Authors:  Joseph T Hanlon; Jennifer Tjia
Journal:  Sr Care Pharm       Date:  2021-03-01

8.  A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse.

Authors:  Mark Abie Horowitz; Sameer Jauhar; Sridhar Natesan; Robin M Murray; David Taylor
Journal:  Schizophr Bull       Date:  2021-07-08       Impact factor: 7.348

9.  Carbetocin is a Functional Selective Gq Agonist That Does Not Promote Oxytocin Receptor Recycling After Inducing β-Arrestin-Independent Internalisation.

Authors:  I Passoni; M Leonzino; V Gigliucci; B Chini; M Busnelli
Journal:  J Neuroendocrinol       Date:  2016-04       Impact factor: 3.627

10.  Statin utilisation in a real-world setting: a retrospective analysis in relation to arterial and cardiovascular autonomic function.

Authors:  John D Sluyter; Alun D Hughes; Andrew Lowe; Carlos A Camargo; Robert K R Scragg
Journal:  Pharmacol Res Perspect       Date:  2016-11-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.